Head to Head Contrast: Protalix BioTherapeutics (NYSE:PLX) vs. Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Anixa Biosciences and Protalix BioTherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1	1	3	0	2.40
Protalix BioTherapeutics	0	0	1	0	3.00

Anixa Biosciences currently has a consensus target price of $8.00, indicating a potential upside of 206.51%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 368.75%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Anixa Biosciences.

Profitability

This table compares Anixa Biosciences and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Volatility & Risk

Anixa Biosciences has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.

Earnings & Valuation

This table compares Anixa Biosciences and Protalix BioTherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210,000.00	432.02	-$10.93 million	($0.32)	-8.16
Protalix BioTherapeutics	$80.62 million	2.56	$8.31 million	$0.23	11.13

Protalix BioTherapeutics has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.